https://zenflexwire.com/press-releases/structure-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlightsZenFlex Wireen2026-11-09T21:39:00.165ZStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights https://zenflexwire.com/press-releases/new-data-at-aha-2026-demonstrates-the-value-of-treatment-with-repathar-earlier-in-theZenFlex Wireen2026-11-09T21:24:00.285ZNEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM https://zenflexwire.com/press-releases/werewolf-therapeutics-clinical-data-for-wtx-124-and-wtx-330-presented-at-the-society-forZenFlex Wireen2026-11-09T14:52:08.718ZWerewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting https://zenflexwire.com/press-releases/jasper-therapeutics-inc-announces-results-of-theZenFlex Wireen2026-11-09T13:32:14.841ZJASPER THERAPEUTICS, INC. ANNOUNCES RESULTS OF THE https://zenflexwire.com/press-releases/novo-post-hoc-analysis-finds-wegovyr-24-mg-was-associated-with-improvements-in-liverZenFlex Wireen2026-11-08T19:37:50.150ZNovo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026 https://zenflexwire.com/roundups/health-and-medical-week-of-nov-2-2026ZenFlex Wireen2026-11-09T15:54:00.000ZCVS Health plans split as Q3 earnings dominate health news https://zenflexwire.com/roundups/retail-and-consumer-week-of-nov-2-2026ZenFlex Wireen2026-11-09T14:21:08.017ZQ3 results show mixed outlooks: the week in retail and consumer https://zenflexwire.com/roundups/biotech-and-pharma-week-of-nov-2-2026ZenFlex Wireen2026-11-09T14:20:46.938ZQ3 earnings, FDA filings and GLP-1 deals: the week in biotech